Jazz Pharmaceuticals' $1.32B Acquisition: What Investors Need to Know
Jazz Pharmaceuticals is set to acquire Actio Biosciences for $1.32 billion, a move that could reshape its market position.
Spectral Medical (TSX: EDT) Announces Q2 2026 Results and FDA Progress: A Game Changer for Investors
Spectral Medical's Q2 2026 results and FDA advancements could redefine shareholder value and commerc…
iRhythm's Strong Q2 Earnings and Vital Connect Acquisition: A Sign of Growth
iRhythm's Q2 earnings beat and acquisition of Vital Connect signal promising growth in wearable heal…
Eli Lilly's Next-Gen Weight-Loss Drug Filing: A Game Changer for Investors
Eli Lilly's FDA filing for a new weight-loss drug could reshape the market landscape and challenge c…
Celsius Holdings Soars on Rockstar Energy Founder’s Stake Acquisition
Russ Savage's acquisition of a stake in Celsius Holdings sparks speculation and market movement.
NRx Pharmaceuticals Moves Closer to Launching Preservative-Free Ketamine
NRx Pharmaceuticals' ANDA for preservative-free ketamine passes FDA first-cycle review, signaling si…
Moderna's mRNA Flu Vaccine Approval: A Milestone with Market Implications
Moderna's recent FDA approval for its mRNA flu vaccine marks a significant step, yet market sentimen…
Critical Minerals in Focus: Trump's Meeting with Mining CEOs and Its Market Implications
The Trump administration's focus on critical minerals highlights opportunities for investors in Lomi…
US Jobs Report Shock: What the -23K Non-Farm Payrolls Mean for Markets
The unexpected -23,000 non-farm payrolls in July raises questions about market stability and economi…
Harrow's Strategic Acquisition of TYRVAYA: A Game-Changer for Ophthalmic Treatments
Harrow's acquisition of TYRVAYA positions it as a key player in ophthalmic treatments, offering pote…